Breast Cancer | Specialty

Dr. Edith Perez on Etirinotecan Pegol for HER2-Negative Breast Cancer

January 22nd 2015

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.

Trastuzumab Regimen Lowers Recurrence Risk in Early-Stage, HER2-Positive Breast Cancer

January 20th 2015

Results of a phase II study showed that women with small, stage I HER2-positive tumors who received a combination of lower-intensity chemotherapy and the targeted drug trastuzumab following surgery were highly unlikely to have the cancer recur within 3 years.

Moving Beyond Targeted Therapy Stalwarts: Experts Weigh In on Four Tumor Types

January 19th 2015

OncologyLive asked experts in lymphoma, chronic myeloid leukemia, breast cancer, and non–small cell lung cancer to discuss the impact that the first targeted agents have had on these malignancies and the prospects for new therapeutic approaches.

BRCA Testing and Contralateral Prophylactic Mastectomy

January 13th 2015

Determination of BRCA1 and 2 mutation carrier status has become increasingly important. Estimates suggest that about 80% of breast cancers and 90% of ovarian cancers are sporadic; while only 5% to 10% of breast cancers are hereditary.

BRCA Pioneer Offit Shares Insights on Evolving Testing Landscape

January 7th 2015

For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.

Dr. Arteaga on PI3K Pathway Inhibitors

January 6th 2015

Carlos Arteaga, MD, assistant director, Clinical Research, director, Breast Cancer program, Vanderbilt-Ingram Cancer Center, discusses the PI3K pathway and the role of therapeutic inhibitors in reducing the progression of breast cancer.

CTC Testing Offers Current Value and Future Promise in MBC

January 6th 2015

Circulating tumor cell (CTC) enumeration is a strong prognostic factor in metastatic breast cancer (MBC) and predicts treatment failure.

Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer

December 31st 2014

Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

Lackluster T-DM1 Results Surprise Perez

December 22nd 2014

Researchers will dissect topline results from the MARIANNE trial in the coming weeks in an effort to understand why T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to triumph as a first-line treatment in the metastatic setting for patients with advanced HER2-positive breast cancer despite the promise of earlier findings

HCI Connects Precision Medicine With Patient-Centered Care

December 19th 2014

Latest News & Insight: December 19, 2014

December 19th 2014

Frontline T-DM1 Results Disappointing in Phase III MARIANNE Trial

December 19th 2014

Two HER2-targeting regimens anchored by T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to outperform the standard strategy in women with previously untreated advanced HER2-positive breast cancer in the MARIANNE trial, dealing a blow to efforts to move the drug into frontline settings.

Dr. Overmoyer on Inflammatory Triple-Negative Breast Cancer

December 19th 2014

Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.

Dr. Gradishar Discusses the Results of the BOLERO-1 Trial

December 17th 2014

William J. Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the BOLERO-1 Trial.

Dr. Chlebowski on How Weight Loss Improves TNBC Survival

December 16th 2014

As few as five pounds of weight loss can make a significant difference for patients with triple-negative breast cancer, says Rowan Chlebowski, MD, PhD, a medical oncologist at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center.

The New BRCA1/2 Landscape

December 13th 2014

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing, thrust into the limelight by a high-profile court battle and a celebrity's disclosure.

Gene Test Predicts DCIS Recurrence Risk

December 12th 2014

A 12-gene test for breast cancer recurrence after ductal carcinoma in situ (DCIS) distinguished high- and intermediate- risk patients from those with a low risk

Women With Triple-Negative Breast Cancer May Reap Greater Survival Benefit From Nutrition Intervention

December 12th 2014

Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54% when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.

HR-Negative Subgroup Data Offer Silver Lining to Everolimus Frontline Failure in BOLERO-1

December 12th 2014

Frontline treatment with everolimus (Afinitor) combined with trastuzumab (Herceptin) and paclitaxel failed to delay disease progression versus trastuzumab and paclitaxel alone in patients with HER2-positive advanced breast cancer

Upfront Fulvestrant Improves Survival Over Anastrozole in HR-Positive MBC

December 12th 2014

Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer